CNBC Pro

Investors bet on obesity drugs before without much success. Why this next wave could be different

Josephine Flood | CNBC

It's been nearly a decade since the American Medical Association declared obesity a disease, but treating it has been complicated and muddled by the lingering perception that the condition is more about lifestyle and appearance than biology.

New obesity therapies are drawing a clearer line between mechanisms in the body and the difficulty some have losing weight — demonstrating hurdles no amount of willpower can overcome. The treatments are making greater amounts of weight loss possible, offering patients hope and investors a potential opportunity.

More In Deep Dives

The perils and promise of quantum computing are nearing. Here are ways to invest
CNBC ProThe perils and promise of quantum computing are nearing. Here are ways to invest
How to invest in the education tech trend as schools spend billions to close the Covid learning gap
CNBC ProHow to invest in the education tech trend as schools spend billions to close the Covid learning gap
These common myths about Ethereum's 'Merge' could trip up investors
CNBC ProThese common myths about Ethereum's 'Merge' could trip up investors